恩度联合顺铂局部治疗对非小细胞肺癌合并恶性胸腔积液肿瘤标志物的影响  

Effect of Endo and Cisplatin Local Therapy on Tumor Markers of Non-small Cell Lung Cancer with Malignant Pleural Effusion

作　　者：王会敏 徐克[2] 穆红[1] WANG Hui-min;XU Ke;MU Hong(Department of Laboratory Medicine,Tianjin First Central Hospital,Tianjin 300190,China;General Hospital of Tianjin Medical University/Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment,Tianjin 300052,China)

机构地区：[1]天津市第一中心医院检验科,天津300190 [2]天津医科大学总医院/天津市肺癌转移与肿瘤微环境重点实验室,天津300052

出　　处：《医学信息》2021年第16期106-108,共3页Journal of Medical Information

基　　金：天津市自然科学基金重点项目(编号:18JCZDJC98500);天津市第一中心医院院内课题项目(编号:2019CM16)。

摘　　要：目的分析恩度联合顺铂局部治疗对非小细胞肺癌(NSCLC)合并恶性胸腔积液(MPE)肿瘤标志物的影响。方法回顾性分析2018年10月~2020年12月我院收治的NSCLC合并MPE化疗患者73例,根据治疗方案不同分为联合组36例和参照组37例。参照组给予顺铂治疗,联合组在参照组基础上联合恩度治疗,比较两组治疗疗效、肿瘤标志物指标水平、肺功能、生活质量及不良反应发生情况。结果联合组治疗总有效率为80.56%,高于参照组的64.86%,差异有统计学意义(P<0.05);治疗后,联合组CEA、NSE、VEGF低于参照组,差异有统计学意义(P<0.05);联合组FEV1、FVC、FEV1/FVC水平、QOL评分高于参照组,差异有统计学意义(P<0.05);联合组不良反应发生率为11.11%,低于参照组的21.62%,差异有统计学意义(P<0.05)。结论恩度联合顺铂局部治疗NSCLC合并MPE效果理想,可降低肿瘤标志物水平,减轻肺部损伤,改善患者生活质量,降低不良反应发生情况,具有应用安全性。Objective To analyze the effect of Endo combined with cisplatin local treatment on tumor markers of non-small cell lung cancer(NSCLC)complicated with malignant pleural effusion(MPE).Methods A retrospective analysis of 73 NSCLC patients with MPE chemotherapy admitted to our hospital from October 2018 to December 2020 was divided into a combination group of 36 cases and a reference group of 37 cases according to different treatment options.The reference group was given cisplatin treatment,and the combination group was combined with Endo treatment on the basis of the reference group.The treatment efficacy,tumor marker index levels,lung function,quality of life,and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the combined group was 80.56%,which was higher than 64.86%in the reference group,the difference was statistically significant(P<0.05);After treatment,CEA,NSE,and VEGF in the combined group were lower than those in the reference group,the difference was statistically significant(P<0.05);The FEV1,FVC,FEV1/FVC levels and QOL scores of the combined group were higher than those of the reference group,the difference was statistically significant(P<0.05);The incidence of adverse reactions in the combined group was 11.11%,which was lower than 21.62%in the reference group,the difference was statistically significant(P<0.05).Conclusion Endo combined with cisplatin is effective in the local treatment of NSCLC with malignant MPE.It can reduce the level of tumor markers,reduce lung damage,improve the quality of life of patients,reduce the occurrence of adverse reactions,and has application safety.

关 键 词：非小细胞肺癌 恶性胸腔积液 肿瘤标志物 肺功能 

分 类 号：R734.2[医药卫生—肿瘤]